trwee sdfsdf asdf sadfasd fhhhh!111234567
I am the FIRST
regular 4 post ff
infinite scroll 4 pff
Oct. 28, 2020 11:53PM EST
Supreme Court rejects GOP push to cut absentee ballots deadline in N.C.
The Supreme Court on Wednesday rejected an attempt by conservatives to shorten North Carolina's deadline for mail-in ballots from nine to three days.
The big picture: This is the latest of a series of decisions over mail-in ballot deadlines in various states.
- The decision comes two days after the court rejected an effort by Wisconsin Democrats and civil rights groups to extend that state's deadline for counting absentee ballots to six days post-Election Day.
Of note: Justices Neil Gorsuch, Clarence Thomas and Samuel Alito dissented the latest ruling in a 5-3 vote.
Editor's note: This is a developing news story. Please check back for updates.
Keep reading...Show less
May. 17, 2021 11:06AM EST
Sanofi, GSK COVID vaccine shows strong immune response in phase 2 trials
Sanofi and GSK announcedthis morning their COVID-19 vaccine candidate demonstrated a strong immune response in adults in a phase 2 clinical trial.
Why it matters: Sanofi and GSK say their recombinant protein-based vaccine candidate could ultimately serve as a universal COVID-19 vaccine booster, able to boost immunity regardless of the vaccination first received.
- It could also ultimately help ease the ongoing global supply needs for vaccines.
Details: Sanofi and GSK said the vaccine triggered an antibody response in 95% to 100% of all the trial participants, ages 18 to 95, who got the vaccine.
- The companies also observed a "high immune response after a single dose in patients" who previously recovered from COVID-19, which shows the vaccine has strong booster potential.
- It's a promising development after the companies had to delay their vaccine in December to improve immune response in older adults. Still, it's also important to point out this is a phase 2 clinical trial, a relatively small study with 722 volunteers in the U.S. and Honduras.
A global Phase 3 trial with more than 35,000 participants from various countries is expected to start in the coming weeks to test the efficacy of two vaccine formulations against variants, officials said.
- In parallel, the companies also plan to conduct booster studies.
- Should the candidate prove successful in clearing Phase 3 testing and other regulatory hurdles, officials said a vaccine could be approved by the end of 2021.
Keep reading...Show less
Dec. 10, 2024 10:12AM EST
Dec. 08, 2024 10:04PM EST